Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leftover tumor after breast cancer treatment: a hidden risk revealed

NCT ID NCT07714382

Knowledge-focused Sponsor: Sohag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study looks back at medical records of women with triple-negative breast cancer who had chemotherapy and radiation before surgery. It focuses on those who still had cancer cells left after treatment (residual disease) and tracks how long they lived without the cancer coming back. The goal is to understand which factors are linked to worse outcomes, so doctors can better identify who needs more aggressive follow-up.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help identify which patients with residual TNBC are at highest risk, guiding more personalized follow-up and treatment decisions.
What could go wrong
As a retrospective study, it can show associations but not prove cause and effect. Results may be limited by the quality and completeness of medical records.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

100 people

The number who actually took part.

Started

May 2026

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult female patients with histologically confirmed triple-negative breast cancer (TNBC) who received neoadjuvant systemic therapy followed by definitive surgery and were treated at the study institution during the study period. Data will be collected retrospectively from medical records to evaluate the association between residual disease after neoadjuvant therapy and survival outcomes.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female patients aged ≥18 years. Histologically confirmed triple-negative breast cancer (TNBC). Received standard neoadjuvant systemic therapy. Underwent definitive breast surgery after completion of neoadjuvant therapy. Availability of postoperative pathological assessment documenting residual disease or pathological complete response (pCR). Complete clinical, pathological, treatment, and follow-up data available in the medical records. Exclusion Criteria: * Patients with metastatic disease at initial diagnosis. Patients who did not complete neoadjuvant therapy or did not undergo definitive surgery. Patients with incomplete or missing essential clinical, pathological, or follow-up data. Patients with a history of another primary malignancy that could affect survival analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Triple negative breast cancer (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Triple negative breast cancer (TNBC)

Contacts and locations

Locations

  • Sohag university

    Sohag, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.